Susan Dexter Sonnet Bio Therapeutics Holdings, Inc. (SONN) insider trading activity

Susan Dexter is Director of Sonnet BioTherapeutics Holdings, Inc.. Currently has a direct ownership of 0 shares of SONN, which is worth approximately $0. The most recent transaction as insider was on Dec 02, 2025, when has been sold 9,643 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

100.0% 3M change

100.0% 12M change

Total Value Held $0

Susan Dexter Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 02 2025	SELL Sale (or disposition) back to the issuer	-	9,643 Reduced 100.0%	0 Common Stock
Jul 11 2025	BUY Grant, award, or other acquisition	-	8,000 Added 45.34%	9,643 Common Stock
Dec 11 2023	BUY Grant, award, or other acquisition	-	1,452 Added 46.91%	1,643 Common Stock
Jun 14 2023	BUY Open market or private purchase	$7,000 $0.7 p/Share	10,000 Added 22.9%	33,667 Common Stock
Jan 07 2023	SELL Sale (or disposition) back to the issuer	-	14,627 Reduced 61.8%	9,040 Common Stock
Jan 07 2023	BUY Grant, award, or other acquisition	-	14,627 Added 38.2%	23,667 Common Stock
Dec 14 2022	BUY Grant, award, or other acquisition	-	14,627 Added 9.39%	141,199 Common Stock

Dec 15 2021	BUY Grant, award, or other acquisition	-	63,104 Added 33.27%	126,572 Common Stock
May 25 2021	SELL Payment of exercise price or tax liability	$15,319 $1.51 p/Share	10,145 Reduced 13.78%	63,468 Common Stock

Susan Dexter

Director

Princeton,, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SONN shares.

Notify only if

Value

Insider Trading

Get notified when an Sonnet Bio Therapeutics Holdings, Inc. insider buys or sells SONN shares.

Notify only if

Operation

Value

Type

News

Receive news related to Sonnet BioTherapeutics Holdings, Inc.

Track Activities on SONN

Account